Develops opioid pain drugs that resist abuse and overdose.
Jun 2026Revenue $4.50M/yrExpenses $17.2M/yr
No trendCash runway ≈ 1 month from Jun 2026
Figures by year
When will Ensysce Biosciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $4.50M and expenses $17.2M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $5.07M | $15.3M | −$10.2M |
| Dec 2024 | $5.21M | $11.9M | −$6.73M |
| Dec 2023 | $2.23M | $12.9M | −$10.7M |
| Dec 2022 | $2.52M | $26.7M | −$24.2M |
| Dec 2021 | $3.53M | $23.4M | −$19.9M |
| Dec 2020 | $3.93M | $5.54M | −$1.61M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.